Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”

Relmada Therapeutics' RELIANCE III trial studying REL-1017 as a treatment for Major Depressive Disorder failed to hit the primary endpoint, the company announced Thursday. At some study sites, there were “paradoxical results," Relmada reported.